Literature DB >> 12239290

Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

V Novitsky1, H Cao, N Rybak, P Gilbert, M F McLane, S Gaolekwe, T Peter, I Thior, T Ndung'u, R Marlink, T H Lee, M Essex.   

Abstract

A systematic analysis of immune responses on a population level is critical for a human immunodeficiency virus type 1 (HIV-1) vaccine design. Our studies in Botswana on (i) molecular analysis of the HIV-1 subtype C (HIV-1C) epidemic, (ii) frequencies of major histocompatibility complex class I HLA types, and (iii) cytotoxic T-lymphocyte (CTL) responses in the course of natural infection allowed us to address HIV-1C-specific immune responses on a population level. We analyzed the magnitude and frequency of the gamma interferon ELISPOT-based CTL responses and translated them into normalized cumulative CTL responses. The introduction of population-based cumulative CTL responses reflected both (i) essentials of the predominant virus circulating locally in Botswana and (ii) specificities of the genetic background of the Botswana population, and it allowed the identification of immunodominant regions across the entire HIV-1C. The most robust and vigorous immune responses were found within the HIV-1C proteins Gag p24, Vpr, Tat, and Nef. In addition, moderately strong responses were scattered across Gag p24, Pol reverse transcriptase and integrase, Vif, Tat, Env gp120 and gp41, and Nef. Assuming that at least some of the immune responses are protective, these identified immunodominant regions could be utilized in designing an HIV vaccine candidate for the population of southern Africa. Targeting multiple immunodominant regions should improve the overall vaccine immunogenicity in the local population and minimize viral escape from immune recognition. Furthermore, the analysis of HIV-1C-specific immune responses on a population level represents a comprehensive systematic approach in HIV vaccine design and should be considered for other HIV-1 subtypes and/or different geographic areas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239290      PMCID: PMC136554          DOI: 10.1128/jvi.76.20.10155-10168.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  92 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda.

Authors:  H Cao; I Mani; R Vincent; R Mugerwa; P Mugyenyi; P Kanki; J Ellner; B D Walker
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

3.  Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens.

Authors:  R S Friedman; F R Frankel; Z Xu; J Lieberman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Hierarchies of antigen-specific cytotoxic T-cell responses.

Authors:  A Gallimore; H Hengartner; R Zinkernagel
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

5.  Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Authors:  P J Goulder; M M Addo; M A Altfeld; E S Rosenberg; Y Tang; U Govender; N Mngqundaniso; K Annamalai; T U Vogel; M Hammond; M Bunce; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.

Authors:  I M Belyakov; L S Wyatt; J D Ahlers; P Earl; C D Pendleton; B L Kelsall; W Strober; B Moss; J A Berzofsky
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana.

Authors:  T Ndung'u; B Renjifo; V A Novitsky; M F McLane; S Gaolekwe; M Essex
Journal:  Virology       Date:  2000-12-20       Impact factor: 3.616

8.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

9.  Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

Authors:  S L Rowland-Jones; T Dong; K R Fowke; J Kimani; P Krausa; H Newell; T Blanchard; K Ariyoshi; J Oyugi; E Ngugi; J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

10.  Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1).

Authors:  J da Silva; A L Hughes
Journal:  Mol Biol Evol       Date:  1998-10       Impact factor: 16.240

View more
  52 in total

1.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

2.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Authors:  Yi Liu; John McNevin; Jianhong Cao; Hong Zhao; Indira Genowati; Kim Wong; Sherry McLaughlin; Matthew D McSweyn; Kurt Diem; Claire E Stevens; Janine Maenza; Hongxia He; David C Nickle; Daniel Shriner; Sarah E Holte; Ann C Collier; Lawrence Corey; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.

Authors:  Anne S De Groot; Daniel S Rivera; Julie A McMurry; Soren Buus; William Martin
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

5.  Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.

Authors:  Sanjay Mendiratta; Madhu Vajpayee; Uma Malhotra; Shweta Kaushik; Lalit Dar; Kamalika Mojumdar; Neeraj Kumar Chauhan; Vishnubhatla Sreenivas
Journal:  Med Microbiol Immunol       Date:  2008-11-05       Impact factor: 3.402

6.  Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.

Authors:  Christof Geldmacher; Ian S Metzler; Sodsai Tovanabutra; Tedi E Asher; Emma Gostick; David R Ambrozak; Constantinos Petrovas; Alexandra Schuetz; Njabulo Ngwenyama; Gustavo Kijak; Leonard Maboko; Michael Hoelscher; Francine McCutchan; David A Price; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2009-06-19       Impact factor: 22.113

7.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

8.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Authors:  Raabya Rossenkhan; Iain J MacLeod; Theresa K Sebunya; Eduardo Castro-Nallar; Mary Fran McLane; Rosemary Musonda; Berhanu A Gashe; Vlad Novitsky; M Essex
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.